HMT advised Premier Research Group Plc (“PRG”) an international pharmaceutical services group on the acquisition of EPA Euro Pharma GmbH (“EPA”) for £3.2 million.
EPA is a contract research organisation (“CRO”), based near Frankfurt, providing a broad range of outsourced clinical services to the biotechnology and pharmaceutical industries. The majority of EPA orders are with German pharmaceutical and biotechnology companies. However, EPA also has contracts with several of the world’s largest multinational pharmaceutical groups.
Dr Simon Yaxley, Chief Executive of Premier Research commented:
“We are delighted with the acquisition of EPA which represents an important step in our strategy of building a leading international contract research organisation. The combination of EPA’s excellent reputation, strong medical and scientific staff and knowledgeable local management with Premier Research’s existing international operations, offers a number of complementary synergies to the enlarged Group and further strengthens Premier Research’s position in the CRO market.”
“EPA is Premier Research’s fourth acquisition and the first since flotation. We are proud to have been involved with PRG from the start and look forward to its continued success.”